Pros and Cons of Adaptive Designs

January 14, 2014

IDDI organized a webinar on Pros and Cons of Adaptive Designs.

  • Topics included:
    • Continual reassessment methods for phase I trials
    • Adaptive Bayesian designs for phase II trials
    • Adaptive sample size increases and adaptive enrichment of phase III trials.

VIEW THE RECORDING OF THE WEBINAR HERE

TO ACCESS THE PRESENTATION OF THIS ON-DEMAND WEBINAR, PLEASE FILL OUT THE FORM BELOW

Pros and Cons of Adaptive Designs

To access the presentation of this on-demand webinar, register to the right

This webinar discussed adaptive designs for phase I, phase II and phase III clinical trials in oncology. The webinar took the form of a debate between two statisticians trying to meet the requirements of an oncologist. The pros and cons of various adaptive designs were discussed.

  • Topics included:
    • Continual reassessment methods for phase I trials,
    • Adaptive Bayesian designs for phase II trials
    • Adaptive sample size increases and adaptive enrichment of phase III trials.

Speakers:

  • Marc Buyse, Founder and Chairman IDDI
  • Tomasz Burzykowski, VP Research, IDDI
  • Everardo Saad, CEO Dendrix, Oncology Consultant IDDI
Presentation of the Webinar: Pros and Cons of Adaptive Designs.

To access the presentation of this on-demand webinar, please fill out this form.

    By submitting this form, you agree to receiving commercial electronic messages such as e-mails from IDDI. For more info, please visit our Privacy Policy. You can unsubscribe at any time by clicking the 'unsubscribe' button at the foot of any e-mail communication from IDDI.

    I authorize IDDI to use my data to contact me for commercial purposes.More information